Does interferon-gamma improve pulmonary function in idiopathic pulmonary fibrosis?

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with limited treatment options.
• A prior study suggested potential benefits of interferon (IFN)-gamma1b for IPF lung function, leading to patient demand for this therapy.
• This has prompted further investigation into IFN-gamma1b's efficacy and safety in IPF patients.

Purpose of the Study:

• To prospectively evaluate the efficacy of long-term treatment with interferon (IFN)-gamma1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis (IPF).
• To assess whether this combination therapy improves lung function parameters or alters the natural course of IPF.
• To document the occurrence and impact of side effects associated with IFN-gamma1b treatment in IPF.

Main Methods:

• A prospective study involving five patients diagnosed with idiopathic pulmonary fibrosis (IPF).
• Patients received subcutaneous interferon (IFN)-gamma1b (200 microg three times weekly) and oral prednisolone (10 mg daily) for 12 months.
• Pulmonary function parameters were monitored throughout the treatment period.

Main Results:

• Only one out of five patients experienced improved pulmonary function during the 12-month treatment.
• Four patients showed disease progression, and one patient died within three months of starting therapy.
• Two patients discontinued treatment early due to adverse side effects and further lung function decline.

Conclusions:

• This study does not support previous findings suggesting that interferon (IFN)-gamma1b and corticosteroid treatment improves lung function in idiopathic pulmonary fibrosis (IPF).
• The observed side effects of IFN-gamma1b treatment can significantly diminish patients' quality of life.
• The combination therapy did not appear to alter the natural, progressive course of IPF in this patient cohort.